# Runners high linked to brains endocannabinoid system, not just endorphins: Study

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/runners-high-linked-to-brains-endocannabinoid-system-not-just-endorphins-study/
> **Published:** 2026-08-09T07:19:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:17:07-04:00
> **Clinical Summary:** Runner's high involves endocannabinoid system activation. Clinical implications for cannabis use in mood, exercise capacity, and patient self-medication patterns.

---

✦ New

CED Clinical Relevance
#72
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.

ResearchNeurology[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/)AnxietySafetyAgingPain

Why This Matters
Clinicians should understand that the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/), not solely endorphins, mediates exercise-induced analgesia and mood improvement, which has implications for counseling patients on non-pharmacological pain and mood management. This finding validates recommending physical activity as a therapeutic intervention while potentially opening discussions about how cannabis affects the same neurobiological pathways that naturally activate during exercise. Patients with [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) or depression may benefit from understanding this mechanism when choosing between pharmaceutical cannabinoids, natural exercise, or combined approaches.

Clinical Summary

Recent neuroscientific research demonstrates that the euphoric sensation associated with exercise, commonly known as “runner’s high,” is mediated by the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) rather than solely by endorphins as previously believed. This finding has significant implications for understanding how cannabinoid signaling in the brain contributes to mood regulation, motivation, and the rewarding aspects of physical activity. For clinicians, this mechanistic insight suggests that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may interact with natural endocannabinoid pathways that are activated during exercise, potentially affecting patients’ exercise tolerance, motivation for physical activity, and mood. Patients using cannabis therapeutically or recreationally should be counseled that cannabinoid use may modulate the same neurobiological reward systems engaged during physical activity, which could influence both the subjective experience of exercise and adherence to exercise-based treatment plans. The practical takeaway for clinicians is to assess [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns when evaluating patients’ physical activity levels and exercise tolerance, recognizing that cannabis may affect the brain’s endocannabinoid-mediated reward pathways that normally reinforce healthy movement.

Dr. Caplan’s Take
“This neuroimaging work adds an important piece to our understanding of exercise physiology, though I’d note we’re still in the early phase of mapping exactly how the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) contributes to the runner’s high in humans. What’s clinically interesting is that this suggests multiple neurobiological pathways are at play, which may eventually help us understand why exercise produces such robust [mental health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) benefits across different populations.”

Clinical Perspective

🧠 The emerging evidence that exercise-induced euphoria involves the endocannabinoid system alongside endorphins adds neurobiological nuance to how we counsel patients on physical activity’s mood benefits. This finding is mechanistically interesting but should be interpreted cautiously, as animal models and neuroimaging studies do not necessarily translate directly to clinical outcomes in diverse patient populations with varying fitness levels, medications, and comorbidities. Notably, patients taking cannabis or cannabinoid-based medications may experience altered endocannabinoid signaling, which could theoretically affect their exercise response, though clinical data on this interaction remain limited. For most patients, the practical implication is straightforward: healthcare providers can continue recommending regular physical activity as a evidence-based intervention for depression and anxiety, now with slightly enhanced understanding of the [neurobiological mechanisms](https://cedclinic.com/cannabis-tolerance-behavioral-models/) at work. This knowledge may also help normalize the rewarding nature of exercise for patients skeptical of its mood-

💬 Join the Conversation

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/)

Have thoughts on this? Share it:

[X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Runners%20high%20linked%20to%20brains%20endocannabinoid%20system%2C%20not%20just%20endorphins%3A%20Study%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72960)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72960)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Runners%20high%20linked%20to%20brains%20endocannabinoid%20system%2C%20not%20just%20endorphins%3A%20Study%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72960)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

📰 Source: [https://www.dinamalar.com/amp/news/kalvimalar-news-en/runner39s-high-linked-to-brain39s-endocannabinoid-system-not-just-endorphins-study/61019](https://www.dinamalar.com/amp/news/kalvimalar-news-en/runner39s-high-linked-to-brain39s-endocannabinoid-system-not-just-endorphins-study/61019)

Further Reading
CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/)
Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/)
CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

[Leave a Message](https://cedclinic.com/contact/)
[Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
[Medical Consulting](https://cedclinic.com/book/)
[Cannabis Care](https://cedclinic.com/book/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).
